8-K

===============================================================================


                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): November 24, 2002

                          BioMarin Pharmaceutical Inc.
             (Exact name of registrant as specified in its charter)


Delaware                            000-26727                        68-0397820
(State or other jurisdiction of   (Commission                     (IRS Employer
incorporation or organization)    File Number)              Identification No.)


371 Bel Marin Keys Boulevard, Suite 210, Novato, California               94949
(Address of principal executive offices)                             (Zip Code)


Registrant's telephone number, including area code:              (415) 884-6700


                                 Not Applicable
                    ---------------------------------------
          (Former name or former address, if changed since last report)
===============================================================================






Item 5.  Other Events.

                  On November 24, 2002, BioMarin Pharmaceutical Inc. (the
"Registrant"), together with its joint venture partner Genzyme General, released
additional data from their ongoing open label Phase 3 extension study of
Aldurazyme. The Registrant's press release issued on November 24, 2002 is
attached hereto as Exhibit 99.1.

Item 7.       Financial Statements, Pro Forma Financial Statements and Exhibits.


         (a)      Financial Statements of Business Acquired.

                  Not Applicable.

         (b)      Pro Forma Financial Information.

                  Not Applicable.

         (c)      Exhibits.

                  Exhibit 99.1 Press Release of the Registrant dated November
                  24, 2002.





                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        BioMarin Pharmaceutical Inc.,
                                        a Delaware corporation


Date: November 26, 2002                By: /s/ Fredric D. Price
                                           --------------------
                                           Fredric D. Price
                                           Chairman and Chief Executive Officer



                                  EXHIBIT INDEX

Exhibit No.            Description

Exhibit 99.1           Press Release of the Registrant dated November 24, 2002.

EX-99

EXHIBIT 99.1

NEWS

CONTACTS:


For BioMarin                          For Genzyme
Joshua Grass (Investors)              Sally  curley (Investors)
(415) 884-6777                        (617) 591-7140

Fredda Malkoff (Media)                Dan Quinn (Media)
Feinstein Kean Healthcare             (617) 591-5849
(617) 577-8110


For Immediate Release:
BioMarin and Genzyme Release Additional Primary Endpoint Data from their
Phase III Open-Label Extension Study of Aldurazyme for MPS I

Novato, CA and Cambridge, MA, November 24, 2002 - BioMarin Pharmaceutical Inc.
(Nasdaq and Swiss SWX New Market: BMRN) and Genzyme General (Nasdaq: GENZ) today
released additional data from their ongoing open-label Phase III extension study
of Aldurazyme(R) (laronidase), an investigational drug for the treatment of
mucopolysaccharidosis I (MPS I).

The companies released data regarding the study's two primary endpoints:
pulmonary function as measured by percent predicted Forced Vital Capacity (FVC);
and endurance as measured by distance covered in the six-minute walk test.
Measurements of these endpoints were taken 36 weeks after the commencement of
the open-label extension study, or a total of 62 weeks after commencement of the
placebo-controlled trial. This new data has recently been submitted to the U.S.
Food and Drug Administration (FDA) for review as part of the Biologics License
Application (BLA) that was submitted on July 26, 2002. The data will also be
submitted to the European Agency for the Evaluation of Medicinal Products
(EMEA).

The 22 patients who received Aldurazyme for 62 weeks demonstrated a mean FVC
change of +5.4 percentage points compared to pre-treatment baseline. In the
six-minute walk test, these patients had a mean +40.0 meter change from
pre-treatment baseline. For both the FVC and the six-minute walk tests, these
results indicate that patients maintained the improvements observed after 50
weeks of Aldurazyme treatment.

After 36 weeks, the 23 patients who received placebo during the
placebo-controlled portion of the trial demonstrated a mean +2.6 percentage
point increase in FVC from their pre-Aldurazyme treatment baseline. Most of the
improvement was observed between Weeks 25 and 36 of the open-label extension
study. In the six-minute walk test, these patients demonstrated a mean +32.4
meter change from pre-treatment baseline, an increase in the improvement
observed following 24 weeks of Aldurazyme treatment.


The safety profile in the extension study has been comparable to the
double-blind period. The most commonly reported adverse events were headache,
rhinitis, and pharyngitis. As previously reported, one patient in the extension
study died of causes considered by the principal investigator to be unrelated to
Aldurazyme.

Recent Developments

On October 28, 2002, BioMarin and Genzyme announced that the FDA notified the
companies that the BLA for Aldurazyme will be reviewed by the FDA's
Endocrinologic and Metabolic Drugs Advisory Committee on January 15, 2003. On
September 13, 2002, the FDA granted the Aldurazyme BLA 6-month priority review
status. As a result, the companies anticipate a response from the FDA at the end
of January 2003. The Marketing Authorization Application (MAA) for Aldurazyme is
under review by the European Agency for the EMEA; the companies expect a
response from EMEA in the first half of 2003.

About MPS I

MPS I is a progressive, debilitating and fatal genetic disease caused by a
deficiency of the enzyme alpha-L-iduronidase. This deficiency leads to the
accumulation of complex carbohydrates in the lysosomes of cells, leading to the
progressive dysfunction of cellular, tissue and organ systems. Resulting
symptoms, which span a spectrum of severity, can include impaired cardiac and
pulmonary function, delayed physical development, skeletal and joint
deformities, reduced endurance, and in some cases, delayed mental function. A
majority of patients die before adulthood from complications of the disease.

Aldurazyme is an investigational enzyme replacement therapy for patients with
MPS I, a disease for which no specific drug treatments currently exist.

BioMarin and Genzyme formed a joint venture in 1998 to develop and commercialize
Aldurazyme worldwide. Under the terms of the joint venture, if approved for
commercial sale, BioMarin will manufacture Aldurazyme and Genzyme will have
responsibility for the commercialization of the product. The companies have
obtained Orphan Drug designation and Fast Track status for Aldurazyme for the
treatment of MPS I from the FDA and orphan medicinal product designation from
the EMEA.

Genzyme General develops and markets therapeutic products and diagnostic
products and services. Genzyme General has five therapeutic products on the
market and a strong pipeline of therapeutic products in development focused on
the treatment of genetic diseases and other chronic debilitating disorders with
well-defined patient populations. Genzyme General is a division of Genzyme Corp.

BioMarin Pharmaceutical specializes in the development and commercialization of
therapeutic enzyme products to treat serious, life-threatening diseases and
conditions.


This press release contains forward-looking statements, including without
limitation statements about: the results from the 36-week findings of the
open-label extension study (which may differ from the preliminary results
reported in this press release;, the expected timing and the results of the
review by the FDA of the BLA for Aldurazyme and by the EMEA of the MMA for
Aldurazyme; plans to submit additional data to the EMEA; the anticipated timing
of the FDA advisory committee meeting, and commercialization plans. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially from those projected in these forward-looking
statements. These risks and uncertainties include, among others: the results and
timing of the on-going open-label Phase III extension trial; the content of the
completed BLA filing and MMA filing for Aldurazyme; the content and timing of
decisions made by the FDA advisory committee, the FDA and the EMEA regarding
Aldurazyme; the ability to manufacture sufficient quantities of product for
development and commercialization activities and to do so in a timely manner;
enrollment rates for clinical trials; the continued funding of the joint venture
between Genzyme and BioMarin; decisions made by physicians and third party
payers regarding the use of and reimbursement for Aldurazyme; our ability to
obtain and maintain adequate patent and other proprietary rights protection for
Aldurazyme; the scope, validity and enforceability of patents and other
proprietary rights held by third parties related to therapies for MPS I and the
actual impact of such patents and other rights on our ability to commercialize
Aldurazyme; the competitive environment for therapies for MPS I; and the risks
and uncertainties described in reports filed by Genzyme and BioMarin with the
Securities and Exchange Commission under the Securities Exchange Act of 1934, as
amended, including without limitation the factors contained under the caption
"Factors Affecting Future Operating Results" in Exhibit 99.2 to Genzyme
Corporation's 2001 Annual Report on Form 10-K, as amended. Genzyme General
Division common stock is a series of common stock of Genzyme Corporation.
Therefore, holders of Genzyme General Division common stock are subject to all
of the risks and uncertainties described in Genzyme Corporation reports. Genzyme
and BioMarin caution investors not to place undue reliance on the
forward-looking statements contained in this press release. These statements
speak only as of the date of this press release, and Genzyme and BioMarin
undertake no obligation to update or revise the statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. Aldurazyme(R) is a
trademark of BioMarin/Genzyme LLC. All rights reserved.

BioMarin's press releases and other company information are available online at
http://www.biomarinpharm.com. Information on our website is not incorporated by
reference into this press release.

 Genzyme's press releases and other company information are available at
www.genzyme.com and by calling Genzyme's investor information line at
1-800-905-4369 within the United States or 1-703-797-1866 outside the United
States.